Gerd KULLAK-UBLICK GROUP    SITE

  • Int J Mol Sci. 2020;21:7890. Organic Cation Transporters in human physiology, pharmacology, and toxicology. Samodelov SL, Kullak-Ublick GA, Gai Z, Visentin M. PubMed
  • J Pharmacol Exp Ther. 2020:375:239-246. Untargeted metabolomics reveals anaerobic glycolysis as a novel target of the hepatotoxic antidepressant nefazodone. Krajnc E, Visentin M, Gai Z, Stieger B, Samodelov SL, Häusler S, Kullak-Ublick GA. PubMed
  • Mol Pharmacol. 2020;97:314-323. Obeticholic acid ameliorates Valproic Acid-induced hepatic steatosis and oxidative stress. Gai Z, Krajnc E, Samodelov SL, Visentin M, Kullak-Ublick GA. PubMed
  • J Pharmacol Exp Ther. 2020;372:46-53. Plasma membrane cholesterol regulates the allosteric binding of 1-Methyl-4-Phenylpyridinium to Organic Cation Transporter 2 (SLC22A2). Hörmann S, Gai Z, Kullak-Ublick GA, Visentin M. PubMed
  • Nat Rev Dis Primers. 2019;5:58. Drug-induced liver injury. Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, Aithal GP. PubMed
  • Pharmacol Res. 2020;154:104234. Drugs and hepatic transporters: A review. Jetter A, Kullak-Ublick GA. PubMed
  • Nat Rev Dis Primers. 2019;5:58. Drug-induced liver injury. Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, Aithal GP. PubMed
  • Liver Int. 2019;39:2350-2359. microRNA-206 modulates the hepatic expression of the organic anion-transporting polypeptide 1B1. El Saadany T, van Rosmalen B, Gai Z, Hiller C, Verheij J, Stieger B, van Gulik T, Visentin M, Kullak-Ublick GA. PubMed
  • Pharmacol Res. 2020;154:104234. Drugs and hepatic transporters: A review. Jetter A, Kullak-Ublick GA. PubMed
  • J Hepatol. 2019;70:1222-1261. EASL clinical practice guidelines: Drug-induced liver injury. Andrade RJ, Aithal GP, Björnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, Karlsen TH. PubMed
  • Gastroenterology. 2019;156:1707-1716.e2. A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Cirulli ET, Nicoletti P, Abramson K, Andrade RJ, Bjornsson ES, Chalasani N, Fontana RJ, Hallberg P, Li YJ, Lucena MI, Long N, Molokhia M, Nelson MR, Odin JA, Pirmohamed M, Rafnar T, Serrano J, Stefánsson K, Stolz A, Daly AK, Aithal GP, Watkins PB; Drug-Induced Liver Injury Network (DILIN) investigators; International DILI consortium (iDILIC). PubMed
  • Eur J Clin Pharmacol. 2019;75:409-416. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase. Essers D, Schäublin M, Kullak-Ublick GA, Weiler S. PubMed
  • Drug Discov Today. 2019;24:285-292. Safety differentiation: emerging competitive edge in drug development. Uteng M, Urban L, Brees D, Muller PY, Kullak-Ublick GA, Bouchard P, Tougas G, Chibout SD. PubMed
  • Drug Metab Dispos. 2018;46:1129-1136. Fluorocholine transport mediated by the Organic Cation Transporter 2 (OCT2, SLC22A2): Implication for imaging of kidney tumors. Visentin M, Torozi A, Gai Z, Häusler S, Li C, Hiller C, Schraml PH, Moch H, Kullak-Ublick GA. PubMed
  • Toxicol Sci. 2018;163:265-278. Bile acid sequestration by cholestyramine mitigates FGFR4 inhibition-induced ALT elevation. Schadt HS, Wolf A, Mahl JA, Wuersch K, Couttet P, Schwald M, Fischer A, Lienard M, Emotte C, Teng CH, Skuba E, Richardson TA, Manenti L, Weiss A, Graus Porta D, Fairhurst RA, Kullak-Ublick GA, Chibout SD, Pognan F, Kluwe W, Kinyamu-Akunda J. PubMed
  • Hepatology. 2018; in press. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Church RJ, Kullak-Ublick GA, Aubrecht J, Bonkovsky HL, Chalasani N, Fontana RJ, Goepfert JC, Hackman F, King NMP, Kirby S, Kirby P, Marcinak J, Ormarsdottir S, Schomaker SJ, Schuppe-Koistinen I, Wolenski F, Arber N, Merz M, Sauer JM, Andrade RJ, van Bömmel F, Poynard T, Watkins PB. PubMed
  • PLoS One. 2017;12:e0189436. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. Peta V, Tse C, Perazzo H, Munteanu M, Ngo Y, Ngo A, Ramanujam N, Verglas L, Mallet M, Ratziu V, Thabut D, Rudler M, Thibault V, Schuppe-Koistinen I, Bonnefont-Rousselot D, Hainque B, Imbert-Bismut F, Merz M7,, Kullak-Ublick G, Andrade R, van Boemmel F, Schott E, Poynard T; Drug Induced Liver Injury- Groupe Hospitalier Pitié-Salpêtrière; Drug Induced Liver Group of the Injury Safer and Faster Evidence-based Translation consortium. PubMed
  • Drug Metab Dispos. 2017;45:1240-1244. Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Visentin M, Gai Z, Torozi A, Hiller C, Kullak-Ublick GA. PubMed
  • Biochim Biophys Acta. 2017; S0925-4439(17)30315-0.  Drug-induced bile duct injury. Visentin M, Lenggenhager D, Gai Z, Kullak-Ublick GA. PubMed
  • Gut. 2017;66:1154-1164. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP. PubMed
  • Gastroenterology. 2017;152:1078-1089. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a Genome-Wide Association Study. Nicoletti P and International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium. PubMed
  • Drug Metab Dispos. 2017;45:166-173. Impact of Organic Cation Transporters (OCT-SLC22A) on differential diagnosis of intrahepatic lesions. Liver imaging. Visentin M, van Rosmalen BV, Hiller C, Bieze M, Hofstetter L, Verheij J, Kullak-Ublick GA, Koepsell H, Phoa SS, Tamai I, Bennink RJ, van Gulik TM, Stieger B. PubMed
  • Life Sci. 2016;156:47-56. Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. Krattinger R, Boström A, Lee SM, Thasler WE, Schiöth HB, Kullak-Ublick GA, Mwinyi J. PubMed
  • Am J Physiol Gastrointest Liver Physiol. 2016;310:G1044-51. microRNA-192 suppresses the expression of the farnesoid X receptor. Krattinger R, Boström A, Schiöth HB, Thasler WE, Mwinyi J, Kullak-Ublick GA. PubMed
  • Clin Res Hepatol Gastroenterol. 2016;40:257-66. Bile acids in drug induced liver injury: Key players and surrogate markers. Schadt HS, Wolf A, Pognan F, Chibout SD, Merz M, Kullak-Ublick GA. PubMed
  • J Biol Chem. 2016;291:2397-411. Farnesoid X receptor protects against kidney Injury in uninephrectomized obese mice. Gai Z, Gui T, Hiller C, Kullak-Ublick GA. PubMed
  • J Pharmacol Exp Ther. 2015;355:145-51. Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2. Visentin M, Stieger B, Merz M, Kullak-Ublick GA. PubMed
  • F1000Prime Rep. 2015;7:34. Drug-induced liver injury: the dawn of biomarkers? Weiler S, Merz M, Kullak-Ublick GA. PubMed
  • Liver Int. 2015;35:1152-61. The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes. Schaffner CA, Mwinyi J, Gai Z, Thasler WE, Eloranta JJ, Kullak-Ublick GA. PubMed
  • Am J Physiol Renal Physiol. 2014;306:F130-7. Effect of chronic renal failure on the hepatic, intestinal, and renal expression of bile acid transporters. Gai Z, Chu L, Hiller C, Arsenijevic D, Penno CA, Montani JP, Odermatt A, Kullak-Ublick GA. PubMed
  • Transl Res. 2012;160:298-308. Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. Trdan Lušin T, Mrhar A, Stieger B, Kullak-Ublick GA, Marc J, Ostanek B, Zavratnik A, Kristl A, Berginc K, Delić K, Trontelj J. PubMed
  • Am J Physiol Gastrointest Liver Physiol. 2012;302:G123-33. Regulation of the gene encoding the intestinal bile acid transporter ASBT by the caudal-type homeobox proteins CDX1 and CDX2. Ma L, Jüttner M, Kullak-Ublick GA, Eloranta JJ. PubMed
  • J Hepatol. 2011;54:738-45. Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. de Graaf W1, Häusler S, Heger M, van Ginhoven TM, van Cappellen G, Bennink RJ, Kullak-Ublick GA, Hesselmann R, van Gulik TM, Stieger B. PubMed
  • Mol Pharmacol. 2010;78:1079-87. The human organic anion transporter genes OAT5 and OAT7 are transactivated by hepatocyte nuclear factor-1α (HNF-1α). Klein K, Jüngst C, Mwinyi J, Stieger B, Krempler F, Patsch W, Eloranta JJ, Kullak-Ublick GA. PubMed
  • Hepatology. 2010;52:748-61. Pharmacogenetics of drug-induced liver injury. Russmann S, Jetter A, Kullak-Ublick GA. PubMed
  • Curr Med Chem. 2009;16:3041-53. Current concepts of mechanisms in drug-induced hepatotoxicity. Russmann S1, Kullak-Ublick GA, Grattagliano I. PubMed
  • Pharmacogenomics. 2008;9:597-624. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Zaïr ZM1, Eloranta JJ, Stieger B, Kullak-Ublick GA. PubMed
  • Pharmacogenet Genomics. 2007;17:47-60. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, Meier PJ, Pauli-Magnus C. PubMed
  • Pharmacogenet Genomics. 2007;17:47-60.Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, Meier PJ, Pauli-Magnus C. PubMed
  • Drug Metab Dispos. 2006;34:1582-99. Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11). Lang T, Haberl M, Jung D, Drescher A, Schlagenhaufer R, Keil A, Mornhinweg E, Stieger B, Kullak-Ublick GA, Kerb R. PubMed
  • Mol Pharmacol. 2006;70:627-36. Hepatocyte nuclear factor (HNF) 1 and HNF4 mediate hepatic multidrug resistance protein 2 up-regulation during hepatitis C virus gene expression. Qadri I, Iwahashi M, Kullak-Ublick GA, Simon FR. PubMed
  • J Pharmacol Exp Ther. 2006;317:778-85. The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. Saborowski M1, Kullak-Ublick GA, Eloranta JJ. PubMed
  • Methods Enzymol. 2005;400:511-30.Coordinate transcriptional regulation of transport and metabolism. Eloranta JJ1, Meier PJ, Kullak-Ublick GA. PubMed
  • Am J Physiol Gastrointest Liver Physiol. 2006;290:G476-85. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Landrier JF1, Eloranta JJ, Vavricka SR, Kullak-Ublick GA. PubMed
  • Mol Endocrinol. 2006;20:65-79. The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Eloranta JJ, Jung D, Kullak-Ublick GA. PubMed
  • To be continued ..

PubMed

Zürich, Switzerland

Last update: October 2021